KalVista Pharmaceuticals (KALV) Other Accumulated Expenses (2016 - 2025)
KalVista Pharmaceuticals (KALV) reported Other Accumulated Expenses of $681000.0 for Q3 2025, down 48.17% on a YoY basis from $1.3 million in Q3 2024, and down 15.51% sequentially from $806000.0 in Q2 2025.
KalVista Pharmaceuticals (KALV) Other Accumulated Expenses (2016 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 10 years of Other Accumulated Expenses data on file, last reported at $681000.0 in Q3 2025.
- For the quarter ending Q3 2025, Other Accumulated Expenses fell 48.17% year-over-year to $681000.0; the trailing twelve-month figure through Jul 2025 stood at $681000.0 (down 48.17% YoY), and the FY2025 full-year result was $806000.0, up 218.58% from the prior year.
- Other Accumulated Expenses fell to $681000.0 in Q3 2025, from $806000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q3 2024 to a low of $124000.0 in Q1 2021.
- A 5-year average of $365000.0 and a median of $253000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses plunged 55.4% in 2021 and jumped 787.84% in 2024, its largest moves.
- Tracing KALV's Other Accumulated Expenses over 5 years: stood at $190000.0 in 2021, then grew by 17.89% to $224000.0 in 2022, then soared by 40.18% to $314000.0 in 2023, then surged by 120.7% to $693000.0 in 2024, then slipped by 1.73% to $681000.0 in 2025.
- Business Quant data shows KALV's Other Accumulated Expenses at $681000.0 in Q3 2025, $806000.0 in Q2 2025, and $693000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 681,000.00 |
| Apr 30, 2025 | 806,000.00 |
| Dec 31, 2024 | 693,000.00 |
| Oct 31, 2024 | 279,000.00 |
| Jul 31, 2024 | 1.31 Mn |
| Apr 30, 2024 | 253,000.00 |
| Jan 31, 2024 | 135,000.00 |
| Oct 31, 2023 | 314,000.00 |
| Jul 31, 2023 | 148,000.00 |
| Apr 30, 2023 | 198,000.00 |
| Jan 31, 2023 | 293,000.00 |
| Oct 31, 2022 | 224,000.00 |
| Jul 31, 2022 | 218,000.00 |
| Apr 30, 2022 | 308,000.00 |
| Jan 31, 2022 | 187,000.00 |
| Oct 31, 2021 | 190,000.00 |
| Jul 31, 2021 | 180,000.00 |
| Apr 30, 2021 | 390,000.00 |
| Jan 31, 2021 | 124,000.00 |
| Oct 31, 2020 | 78,000.00 |